Organogenesis Holdings Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Canton, MA
ORGO chart
What traders are saying about $ORGO
Latest postsOrganogenesis Holdings Inc. news
- Organogenesis Holdings Inc. Estimates – NASDAQ:ORGO
TradingView ·
- Sugar beet transformation protocol achieves high direct shoot regeneration
Bioengineer.org ·
- Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
Yahoo Finance ·
- Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
Yahoo Finance ·
- Organogenesis (ORGO) Q2 2026 Earnings Call Transcript
fool.com ·
- Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution
Yahoo Finance ·
- Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?
Yahoo Finance ·
- Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary
app.moby.co ·
- Organogenesis Q2 Earnings Call Highlights
marketbeat.com ·
- Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
Yahoo Finance ·
- Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
Yahoo Finance ·
- Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Yahoo Finance ·
Organogenesis Holdings Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $564.2M | $482.0M | $433.1M | $450.9M |
| Net income | $37.0M | $900,000 | $4.9M | $15.5M |
| Diluted EPS | $0.15 | $-0.01 | $0.04 | $0.12 |
| Total assets (year end) | $598.7M | $497.9M | $460.0M | $449.4M |
| Cash and equivalents (year end) | $93.7M | $135.6M | $103.8M | $102.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Organogenesis Holdings Inc.
- Ticker
- ORGO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Canton, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1661181
- Former names
- Avista Healthcare Public Acquisition Corp.
Frequently asked questions
What exchange is Organogenesis Holdings Inc. listed on?
Organogenesis Holdings Inc. trades on the Nasdaq under the ticker symbol ORGO.
What industry is Organogenesis Holdings Inc. in?
Organogenesis Holdings Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Organogenesis Holdings Inc. headquartered?
Organogenesis Holdings Inc.'s business address on file with the SEC is in Canton, MA.
When does Organogenesis Holdings Inc.'s fiscal year end?
Organogenesis Holdings Inc.'s fiscal year ends on December 31.
How much revenue did Organogenesis Holdings Inc. report?
Organogenesis Holdings Inc. reported $564.2M in revenue for calendar year 2025, according to its SEC filings.